SAN DIEGO (PRWEB) August 05, 2021
January Therapeutics announced the appointment of Patrick Kearney, PhD, as Head of Early Research and Development. Dr. Kearney will lead key aspects of the Scientific Team for January’s oncology programs including furthering of the Targeted Oncology Programs, Platform Expansion, and other undisclosed targets.
Dr. Kearney is a former Senior Director of Medicinal Chemistry at Exelixis, where he led teams whose kinase-focused efforts resulted in multiple clinical candidates for oncology and inflammation applications. Additionally, while there, he led both technology development, production, and corporate partnership initiatives to build the company’s screening library. Subsequently, Dr. Kearney founded of HD Sciences to develop nanoparticle-based reagents for use in medicinal chemistry. Immediately prior to joining January Therapeutics, he was a Principal Investigator in Chemistry at Deciphera Pharmaceuticals, where led a team to identify novel kinase inhibitors with that company’s core technology platform.
Dr. Kearney received his B.S. from Carnegie Mellon University and a Ph.D. in Chemistry from the California Institute of Technology. He is listed as an inventor on 20 patent applications and as an author on 17 peer-reviewed articles.
“We are very pleased to welcome Dr. Kearney to January.” said Sam Ellis, CEO of January Therapeutics. “His deep therapeutic knowledge combined with industry experience and advocacy for translational medicine in biotech will bring world class expertise to help patients with cancer. His ability to build teams, and bring success will help January Therapeutics grow to the next level.”
January Therapeutics is a biotechnology company focused on discovering novel therapeutics that leverage the proven clinical benefits of albumin-based nanoparticle formulation. Their initial development programs are focused on oncology, specifically related to therapeutics that treat sarcomas, ovarian, lung and other solid tumors. To learn more, visit https://januarytx.com.
Sam Ellis, CEO